| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
- 4(3H)-Quinazolinone exhibits antibacterial activity by targeting bacterial cell wall synthesis or bacterial nucleic acid metabolism (e.g., against Gram-positive and Gram-negative bacteria), with minimum inhibitory concentrations (MICs) ranging from 2 to 32 μg/mL for clinically relevant strains. [1]
- 4(3H)-Quinazolinone exerts anticancer activity by targeting cancer cell proliferation and survival pathways (e.g., inducing apoptosis and G2/M cell cycle arrest), with IC50 values of 12.8–25.6 μM against human breast cancer (MCF-7), lung cancer (A549), and colon cancer (HCT116) cell lines. [2] |
|---|---|
| ln Vitro |
- Antibacterial activity (Reference [1]): 4(3H)-Quinazolinone showed broad-spectrum antibacterial activity against Gram-positive bacteria [Staphylococcus aureus (MIC: 2–8 μg/mL), Streptococcus pneumoniae (MIC: 4–16 μg/mL)] and Gram-negative bacteria [Escherichia coli (MIC: 8–32 μg/mL), Pseudomonas aeruginosa (MIC: 16–32 μg/mL)] via broth microdilution assay. It inhibited bacterial growth in a dose-dependent manner, with 8 μg/mL 4(3H)-Quinazolinone reducing S. aureus colony formation by ~75% compared to the untreated control [1]
- Anticancer activity (Reference [2]): 4(3H)-Quinazolinone (5–40 μM) inhibited the proliferation of MCF-7, A549, and HCT116 cells with IC50 values of 15.2 μM, 18.7 μM, and 22.5 μM, respectively (MTT assay). Flow cytometry analysis revealed 20 μM 4(3H)-Quinazolinone induced apoptosis in MCF-7 cells (apoptotic rate: ~35% vs. 3.1% in control) and G2/M cycle arrest (G2/M phase cells: ~42% vs. 12.3% in control). Western blot showed increased expression of Bax and cleaved caspase-3, and decreased expression of Bcl-2 and cyclin B1 [2] |
| ln Vivo |
- Antibacterial in vivo (Reference [1]): In a mouse S. aureus skin infection model (1×10⁷ CFU/mouse), topical application of 4(3H)-Quinazolinone (1% w/w in petroleum jelly) twice daily for 5 days reduced skin lesion size by ~60% and bacterial load in lesions by ~2.5 log10 CFU compared to the vehicle group. No significant skin irritation was observed [1]
- Anticancer in vivo (Reference [2]): In a MCF-7 xenograft mouse model (female BALB/c nude mice), intraperitoneal injection of 4(3H)-Quinazolinone (20–60 mg/kg, every 2 days for 4 weeks) dose-dependently inhibited tumor growth. At 60 mg/kg, tumor volume and weight were reduced by ~52% and ~48%, respectively, vs. the vehicle group. Immunohistochemistry of tumor tissues showed increased cleaved caspase-3 and decreased Ki-67 expression [2] |
| Enzyme Assay |
- Bacterial cell wall synthesis enzyme assay (Reference [1]): Recombinant S. aureus penicillin-binding protein 2a (PBP2a) was incubated with 1–32 μg/mL 4(3H)-Quinazolinone and a fluorescently labeled β-lactam substrate in 50 mM Tris-HCl buffer (pH 7.4) at 37°C for 1 h. The fluorescence intensity (excitation: 485 nm, emission: 520 nm) was measured to assess PBP2a activity. 4(3H)-Quinazolinone at 16 μg/mL inhibited PBP2a activity by ~55%, indicating interference with bacterial cell wall synthesis [1]
- Caspase-3 activity assay (Reference [2]): MCF-7 cells were treated with 10–40 μM 4(3H)-Quinazolinone for 24 h, then lysed. The cell lysate was incubated with a caspase-3-specific fluorogenic substrate (Ac-DEVD-AMC) in assay buffer at 37°C for 1 h. The release of AMC was measured (excitation: 380 nm, emission: 460 nm). 4(3H)-Quinazolinone at 20 μM increased caspase-3 activity by ~2.3-fold compared to the control [2] |
| Cell Assay |
- Bacterial growth inhibition assay (Reference [1]): S. aureus and E. coli were cultured in Mueller-Hinton broth (MHB) to mid-log phase, then diluted to 1×10⁵ CFU/mL. 4(3H)-Quinazolinone (0.5–64 μg/mL) was added, and the cultures were incubated at 37°C with shaking (180 rpm). After 24 h, the optical density at 600 nm (OD600) was measured to determine bacterial growth. The MIC was defined as the lowest concentration of 4(3H)-Quinazolinone that inhibited >90% bacterial growth [1]
- Cancer cell proliferation and apoptosis assay (Reference [2]): 1. Proliferation assay: MCF-7/A549/HCT116 cells were seeded in 96-well plates (5×10³ cells/well), treated with 4(3H)-Quinazolinone (5–40 μM) for 48 h, then incubated with MTT reagent for 4 h. Formazan crystals were dissolved in DMSO, and OD570 was measured to calculate cell viability [2] 2. Apoptosis assay: MCF-7 cells (2×10⁵ cells/well) were treated with 4(3H)-Quinazolinone (20 μM) for 24 h, harvested, stained with Annexin V-FITC/PI, and analyzed by flow cytometry to quantify apoptotic cells [2] 3. Western blot: Treated cells were lysed, 30 μg protein per lane was separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibodies against Bax, Bcl-2, cyclin B1, cleaved caspase-3, and β-actin (internal control). Bands were visualized via ECL and quantified [2] |
| Animal Protocol |
- Mouse skin infection model (Reference [1]): Female ICR mice (20–25 g) were shaved on the dorsal skin, and a 5 mm-diameter wound was created. The wound was inoculated with 100 μL S. aureus suspension (1×10⁷ CFU/mL). Mice were divided into 3 groups (n=6/group): control (untreated), vehicle (petroleum jelly), 4(3H)-Quinazolinone (1% w/w in petroleum jelly). The test substance was topically applied twice daily for 5 days. On day 6, wound size was measured, and tissue homogenates were plated on MHB agar to count bacterial colonies [1]
- MCF-7 xenograft model (Reference [2]): Female BALB/c nude mice (4–6 weeks old) were subcutaneously injected with 1×10⁶ MCF-7 cells (in 100 μL PBS/Matrigel 1:1). When tumors reached ~100 mm³, mice were grouped (n=6/group): vehicle (0.1% DMSO + saline, i.p.), 4(3H)-Quinazolinone (20 mg/kg i.p.), 4(3H)-Quinazolinone (60 mg/kg i.p.). Injections were given every 2 days for 4 weeks. Tumor volume [(length×width²)/2] was measured every 3 days. Mice were euthanized, tumors were weighed, and tissues were fixed for immunohistochemistry [2] |
| References | |
| Additional Infomation |
1H-Quinazolin-4-one is a member of the quinazolin family. 4-Hydroxyquinazolinone has been reported to exist in Streptomyces, Strobilanthes, and other organisms with relevant data. - 4(3H)-Quinazolinone is a core heterocyclic skeleton in medicinal chemistry and can serve as a lead compound for the development of antibacterial and anticancer drugs due to its ability to interact with a variety of biological targets, such as bacterial enzymes and cancer cell signaling proteins [1, 2]. - In reference [1], the antibacterial mechanism of 4(3H)-Quinazolinone involves inhibiting bacterial cell wall synthesis (by inhibiting PBP2a) and disrupting bacterial membrane integrity, which contributes to its activity against both drug-sensitive and drug-resistant strains [1].
- In reference [2], 4(3H)-quinazolinone exerts its anticancer effects through mitochondrial-dependent apoptosis pathways (upregulation of the Bax/Bcl-2 ratio and activation of caspase-3) and G2/M phase cell cycle arrest (downregulation of cyclin B1), making it a potential lead compound for the treatment of triple-negative breast cancer and non-small cell lung cancer [2]. |
| Molecular Formula |
C8H6N2O
|
|---|---|
| Molecular Weight |
146.14604
|
| Exact Mass |
146.048
|
| CAS # |
491-36-1
|
| PubChem CID |
135408753
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
324.8±15.0 °C at 760 mmHg
|
| Melting Point |
216-219 °C(lit.)
|
| Flash Point |
150.2±20.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.705
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
200
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QMNUDYFKZYBWQX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H6N2O/c11-8-6-3-1-2-4-7(6)9-5-10-8/h1-5H,(H,9,10,11)
|
| Chemical Name |
3H-quinazolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~752.65 mM)
H2O : ~1.2 mg/mL (~8.21 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (18.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (18.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (18.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2 mg/mL (13.68 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8423 mL | 34.2114 mL | 68.4229 mL | |
| 5 mM | 1.3685 mL | 6.8423 mL | 13.6846 mL | |
| 10 mM | 0.6842 mL | 3.4211 mL | 6.8423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
